Pharmacological Targeting of Phosphoinositide Lipid Kinases and Phosphatases in the Immune System: Success, Disappointment and New Opportunities

Pharmacological Targeting of Phosphoinositide Lipid Kinases and Phosphatases in the Immune System: Success, Disappointment and New Opportunities

The predominant expression of the γ and δ isoforms of PI3K in cells of hematopoietic lineage prompted speculation that inhibitors of these isoforms could offer opportunities for selective targeting of PI3K in the immune system in a range of immune-related pathologies. While there has been some su...

Full description

Bibliographic Details
Main Authors:	Stephen Geoffrey Ward, Matthew David Blunt
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2012-08-01
Series:	Frontiers in Immunology
Subjects:	Inflammation Leukemia Lymphocytes inhibitors PI3K activators
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fimmu.2012.00226/full

Similar Items

Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL
by: Valerio Guarente, et al.
Published: (2021-03-01)

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy
by: Lingzhi Zhang, et al.
Published: (2020-12-01)

Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
by: Ebru Aydin, et al.
Published: (2021-01-01)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
by: Visentin A, et al.
Published: (2020-09-01)

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?
by: Jeong Su Park, et al.
Published: (2020-10-01)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
by: Madanat YF, et al.
Published: (2016-03-01)

Investigation of the role of phosphoinositide lipid kinases and phosphatases in T lymphocyte biology
by: Blunt, Matthew David
Published: (2013)

The role of phosphoinositide 3-kinase subunits in chronic thyroiditis
by: Wojciechowska-Durczynska Katarzyna, et al.
Published: (2012-12-01)

The role of Phosphoinositide 3-Kinase in the Regulation of Cardiac Morphology and Function
by: Guo, Danny
Published: (2011)

Pharmacologic and Genetic Investigation of PI3K p110delta in Chronic Lymphocytic Leukemia
by: Dong, Shuai
Published: (2017)

Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors
by: Qin Xia, et al.
Published: (2020-10-01)

Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment
by: David Gyori, et al.
Published: (2017-03-01)

Protein kinase inhibitors for acute leukemia
by: Yuan Ling, et al.
Published: (2018-02-01)

Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
by: Marketa Bloomfield, et al.
Published: (2021-07-01)

Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase
by: Jingxian Liu, et al.
Published: (2019-12-01)

Design, synthesis and molecular mechanisms of novel dual inhibitors of heat shock protein 90/phosphoinositide 3-kinase alpha (Hsp90/PI3Kα) against cutaneous melanoma
by: Feifei Qin, et al.
Published: (2019-01-01)

Regulation of glucose metabolism in T cells; new insight into the role of Phosphoinositide 3-kinases
by: David K Finlay, et al.
Published: (2012-08-01)

A specific role for phosphoinositide 3-kinase and AKT in osteoblasts?
by: Imelda Mary McGonnell, et al.
Published: (2012-07-01)

Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors
by: Minhang Xin, et al.
Published: (2018-01-01)

Phosphoinositide 3′-Kinase γ Facilitates Polyomavirus Infection
by: Paul Clark, et al.
Published: (2020-10-01)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
by: Chiara Tarantelli, et al.
Published: (2020-02-01)

Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas
by: Joanna M. Janus, et al.
Published: (2017-07-01)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
by: Kamelia Hashemzadeh, et al.
Published: (2019-01-01)

Berberine Induced Apoptosis of Human Osteosarcoma Cells by Inhibiting Phosphoinositide 3 Kinase/Protein Kinase B (PI3K/Akt) Signal Pathway Activation
by: Zhi-Ze CHEN
Published: (2016-05-01)

Targeted delivery of a phosphoinositide 3‐kinase γ inhibitor to restore organ function in sepsis
by: Adrian T Press, et al.
Published: (2021-10-01)

Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer
by: Yang F, et al.
Published: (2017-09-01)

Defining the molecular mechanisms mediating class IA phosphoinositide 3-kinase (PI3K) regulation and their role in human disease
by: Dornan, Gillian Leigh
Published: (2019)

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
by: Matthew D. Blunt, et al.
Published: (2015-01-01)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
by: Rhodes JM, et al.
Published: (2021-03-01)

Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies
by: Dimitar G. Efremov, et al.
Published: (2020-05-01)

Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells
by: Meredith J. Layton, et al.
Published: (2014-04-01)

NEURODEGENERATION CAUSED BY TRIMETHYLTIN VIA INHIBITION OF TROPOMYOSIN-RECEPTOR-KINASE B AND PHOSPHOINOSITIDE 3-KINASE/PROTEIN KINASE B SIGNALING CASCADE
by: Tran Phi Hoang Yen, et al.
Published: (2014-04-01)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
by: Xianhui Wang, et al.
Published: (2021-07-01)

Molecular mechanisms controlling SH2 domain-containing inositol 5’phosphatase (SHIP) function in B cells
by: Pauls, Samantha
Published: (2016)

Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors
by: Viviana Mannella, et al.
Published: (2021-03-01)

Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics
by: Divya Murthy, et al.
Published: (2018-04-01)

Naringenin Inhibits Platelet Activation and Arterial Thrombosis Through Inhibition of Phosphoinositide 3-Kinase and Cyclic Nucleotide Signaling
by: Manting Huang, et al.
Published: (2021-08-01)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
by: Lisa Rohrbacher, et al.
Published: (2021-03-01)

Reciprocal regulation among TRPV1 channels and phosphoinositide 3-kinase in response to nerve growth factor
by: Anastasiia Stratiievska, et al.
Published: (2018-12-01)

PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches
by: Matteo Caforio, et al.
Published: (2021-08-01)